Sangamo Therapeutics, Inc. (SGMO) Holdings Raised by State Street Corp

State Street Corp increased its position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 51.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,868,285 shares of the biopharmaceutical company’s stock after buying an additional 636,296 shares during the period. State Street Corp owned about 2.60% of Sangamo Therapeutics worth $16,441,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. HighTower Advisors LLC increased its stake in Sangamo Therapeutics by 0.3% in the first quarter. HighTower Advisors LLC now owns 39,405 shares of the biopharmaceutical company’s stock valued at $206,000 after purchasing an additional 100 shares during the last quarter. Blair William & Co. IL increased its stake in Sangamo Therapeutics by 4.3% in the second quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 500 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Sangamo Therapeutics by 0.4% in the first quarter. Dimensional Fund Advisors LP now owns 128,764 shares of the biopharmaceutical company’s stock valued at $670,000 after purchasing an additional 513 shares during the last quarter. Principal Financial Group Inc. increased its stake in Sangamo Therapeutics by 6.8% in the second quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 832 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its stake in Sangamo Therapeutics by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 267,293 shares of the biopharmaceutical company’s stock valued at $2,353,000 after purchasing an additional 1,558 shares during the last quarter. Hedge funds and other institutional investors own 64.35% of the company’s stock.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) traded down $0.10 during mid-day trading on Wednesday, hitting $16.35. The stock had a trading volume of 1,735,124 shares, compared to its average volume of 1,314,902. Sangamo Therapeutics, Inc. has a 1-year low of $2.65 and a 1-year high of $18.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.64 and a quick ratio of 5.64.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.04. The business had revenue of $11.81 million during the quarter, compared to the consensus estimate of $10.37 million. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The company’s revenue was up 333.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.27) earnings per share. sell-side analysts predict that Sangamo Therapeutics, Inc. will post -0.73 EPS for the current year.

In related news, Director Saira Ramasastry sold 5,000 shares of the stock in a transaction on Friday, November 17th. The stock was sold at an average price of $14.67, for a total transaction of $73,350.00. Following the completion of the sale, the director now directly owns 5,000 shares of the company’s stock, valued at $73,350. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Curt A. Herberts III sold 15,000 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $15.25, for a total value of $228,750.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 67,630 shares of company stock valued at $1,015,812. Corporate insiders own 5.50% of the company’s stock.

Several equities analysts have commented on the stock. Barclays assumed coverage on shares of Sangamo Therapeutics in a research note on Wednesday, November 22nd. They issued an “overweight” rating and a $20.00 price target on the stock. Wedbush reiterated a “hold” rating and issued a $6.00 price target on shares of Sangamo Therapeutics in a research note on Wednesday, November 15th. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Wednesday, November 15th. Piper Jaffray Companies upgraded shares of Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 price target on the stock in a research note on Wednesday, November 15th. Finally, Jefferies Group reissued a “buy” rating and issued a $18.00 price objective on shares of Sangamo Therapeutics in a report on Friday, October 13th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. Sangamo Therapeutics has a consensus rating of “Buy” and an average price target of $17.83.

ILLEGAL ACTIVITY WARNING: “Sangamo Therapeutics, Inc. (SGMO) Holdings Raised by State Street Corp” was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://ledgergazette.com/2017/12/07/state-street-corp-increases-stake-in-sangamo-therapeutics-inc-sgmo.html.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply